Bones & muscles GHRP / ghrelin agonist
GHRP-6
Regulatory status
Status at a glance
503A compounding status
Not nominated
We found no pending nomination for the 503A bulks list. Unless the substance has another legal pathway (for example, a USP monograph or use in an FDA-approved drug), 503A pharmacies generally may not compound with it.
- FDA approval
- Not FDA-approved for any use
- 503B outsourcing
- Not determined
- Anti-doping (WADA)
- On the WADA Prohibited List
- DEA schedule
- Not a controlled substance
About peptide status
Most peptides discussed here are not FDA-approved for any use, and products labeled “research use only” are not for human use. Removal from Category 2 does not authorize compounding. PCAC votes are non-binding recommendations; FDA and HHS make the final decisions.
This is not medical or legal advice, and we do not publish dosing, sourcing or reconstitution information. Talk with a licensed clinician before using any peptide.
If you think you are having a medical emergency, call 911.
Key takeaway
GHRP-6 is one of the original synthetic ghrelin-mimic peptides, sold in the wellness market to raise the body's own growth hormone and stimulate appetite. Human data are limited to short studies of growth hormone release, with no controlled trials proving the marketed muscle, recovery, or anti-aging benefits. As of 2026 it is not FDA-approved and is banned in sport.
At a glance
- FDA status
- Non-FDA-approved peptide sold in the wellness/gray market
- What it is
- Ghrelin-receptor agonist / growth hormone-releasing peptide that markedly increases appetite
- Research
- Human data are limited to short pharmacology studies; the marketed benefits are unproven
- Sport
- Prohibited by WADA at all times
- Evidence strength
- Low research
Summary
GHRP-6 is a synthetic ghrelin-mimic peptide that raises growth hormone and appetite. Learn how it works, what human data exist, and why it is not FDA-approved.
What is GHRP-6?
GHRP-6 is a synthetic six-amino acid peptide and one of the first growth hormone-releasing peptides developed. It is sold through wellness and "research peptide" channels and promoted for muscle gain, recovery, and appetite stimulation. It was never marketed as an approved drug.
How does it work?
GHRP-6 activates the growth hormone secretagogue receptor (the ghrelin receptor), prompting the pituitary to release growth hormone, and it is proposed to act partly by blunting the body's growth-hormone "brake," somatostatin.
Compared with newer peptides it is less selective, notably:
- Increasing appetite
- Modestly raising cortisol
- Modestly raising prolactin
Laboratory work also describes growth hormone secretagogue receptors in heart and blood-vessel tissue, which is the basis for preclinical interest in other effects. The marketed benefits are extrapolated from the growth hormone rise. This describes the proposed mechanism, separate from proven outcomes.
Is it FDA-approved?
Safety note
Status: Non-FDA-approved peptide sold in the wellness/gray market
Category: Wellness and performance · Primary body area: Bones & muscles
No. GHRP-6 is not approved by the FDA and has no approved product. It has been treated as not eligible for routine 503A compounding in the U.S. and is not approved for performance or anti-aging. In sport, growth hormone-releasing peptides including GHRP-6 are prohibited at all times under the WADA list.
What does the research show?
Editor’s note
Evidence strength: Low research
Human data are limited to short studies of growth hormone release, with the marketed wellness benefits resting on animal and laboratory work.
The human evidence is short pharmacology. According to PubMed, an infusion study in healthy men found GHRP-6 raised growth hormone and IGF-1 while the pituitary remained responsive, a hormone-level result rather than a clinical outcome. Cardiovascular and cell-protective effects are described mainly in preclinical work and reviews. No controlled human trials support the marketed muscle, fat, recovery, or anti-aging uses.
Sources: a growth hormone pharmacology study (Jaffe et al., Journal of Clinical Endocrinology & Metabolism, 1993, DOI: 10.1210/jcem.77.6.7903313) and a review of growth hormone secretagogues (Cao et al., Trends in Endocrinology & Metabolism, 2005, DOI: 10.1016/j.tem.2005.11.004), both indexed on PubMed; and the WADA Prohibited List. This document is educational, is not medical advice or a health claim, and is not an offer to sell any product.
Registered human trials
0 registered human trials on ClinicalTrials.gov that we reviewed
Sources
- [1]
- [2]
- [3]
Compare every peptide’s status in the peptide regulatory status database
More for Bones & muscles
View all bones & muscles peptides →- FDA-approved Bones & muscles
Abaloparatide
Abaloparatide is a synthetic 34-amino acid analog of parathyroid hormone-related protein (PTHrP) that activates the PTH1 receptor to stimulate new bone formation. FDA-approved in 2017 as Tymlos, it is a daily injection for postmenopausal women and men with osteoporosis at high fracture risk, and it is capped at two years of use. In the pivotal ACTIVE trial, it cut the risk of new spine fractures by about 86% versus placebo.
- FDA-approved Bones & muscles
Calcitonin-Salmon
Miacalcin (injection), nasal spray sold as a generic
Calcitonin-salmon is an FDA-approved synthetic version of a natural hormone that slows bone breakdown, used mainly for postmenopausal osteoporosis, Paget's disease of bone, and high blood calcium (hypercalcemia). It comes as an injection, sold as Miacalcin, and as a nasal spray sold as a generic. A modest effect on fractures and a small possible cancer risk with long-term use make it a second-line option today.
- Not FDA-approved Bones & muscles
Cjc-1295
CJC-1295 is a synthetic long-acting analog of growth-hormone-releasing hormone (GHRH). In two placebo-controlled trials of healthy adults aged 21 to 61 (Teichman, 2006), a single injection raised mean growth hormone 2- to 10-fold for 6 days or more. Mean IGF-1 rose 1.5- to 3-fold, but no controlled human trial shows benefit for muscle, fat loss, recovery, or anti-aging. CJC-1295 is not FDA-approved, it is not eligible for routine pharmacy compounding, and it is banned in sport.
- FDA-approved Bones & muscles
Etelcalcetide
Etelcalcetide (sold as Parsabiv) is a peptide that activates the calcium-sensing receptor to lower parathyroid hormone, used for secondary hyperparathyroidism in people on dialysis for kidney disease. Unlike parathyroid hormone replacement, it suppresses an overactive parathyroid signal, and it is given intravenously at the end of each dialysis session. It has been FDA-approved in the U.S. since 2017.
- Not FDA-approved Bones & muscles
Follistatin-344
Follistatin-344 is a form of the natural protein follistatin that blocks myostatin, a brake on muscle growth, sold as a "research chemical" in the performance market for muscle gain. The strongest human data come from gene therapy, not the injectable peptide. In a small 2017 trial, six patients with sporadic inclusion body myositis gained a median 56.0 m per year on the 6-minute walk test after follistatin gene therapy, versus a 25.8 m decline in eight matched untreated controls (p = 0.01). It is not FDA-approved and is banned in sport.
- Not FDA-approved Bones & muscles
Ghrp-2
Pralmorelin
GHRP-2 (pralmorelin) is a synthetic ghrelin-mimic peptide that prompts the pituitary to release growth hormone, sold in the wellness market for muscle, recovery, and appetite. Its only genuine validated use is as a diagnostic test of growth hormone capacity (approved in Japan), not as a treatment, and there are no controlled trials supporting the marketed wellness benefits. As of 2026 it is not FDA-approved and is banned in sport.